Traduction de «vascular disease » (Néerlandais → Français) :

TERMINOLOGIE

central-core-disease | congenitale spierdystrofie | NNO | congenitale spierdystrofie | met specifieke morfologische-afwijkingen van spiervezel | fibre-type disproportion | minicore disease | multicore disease | myopathie | myotubulair (centronucleair) | myopathie | nemaline lichaampjes
Disproportion des types de fibres Dystrophie musculaire congénitale:SAI | avec anomalies morphologiques spécifiques des fibres musculaires | Myopathie:à axe central | à bâtonnets [némaline] | de type: mini-core | multi-core | myotubulaire (centro-nucléaire)

ziekte van Franklin | gamma heavy chain disease | Mmu heavy chain disease
Maladie de Franklin

poikiloderma vasculare atrophicans
Poïkilodermie généralisée type Petges-Cléjat [atrophiante vasculaire]

ADTKD-UMOD - UMOD-related autosomal dominant tubulointerstitial kidney disease
néphropathie tubulo-interstitielle autosomique dominante associée à UMOD

Border disease-virus
virus Border disease

Borna disease-virus
virus Borna disease

ADPCLD - autosomal dominant polycystic liver disease
polykystose hépatique isolée

AIED - Åland Islands eye disease
maladie ophtalmique des îles Åland

ADTKD-MUC1 - MUC1-related autosomal dominant tubulointerstitial kidney disease
néphropathie tubulo-intersitielle autosomique dominante associée à MUC1

bovien mucosal disease-virus
virus Bovine mucosal disease

TRADUCTIONS EN CONTEXTE

However, harmful effects associated with long-term vitamin supplementation, particularly in smokers and people with vascular disease, cannot be ruled out.
Bischoff-Ferrari HA, Dawson-Hughes B, Stahelin HB et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised

M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, -0,7 5,4 48.607.976 2,8 NON-STEROIDS C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 16,7 29,3 48.458.787 23,2 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY 4,8 10,5 47.845.796 8,1 VASCULAR EFFECTS L02B HORMONE ANTAGONISTS AND RELATED AGENTS 18,1 16,3 40.001.905 12,5 C01D VASODILATORS USED IN CARDIAC DISEASES -5,3 -0,3 37.257.508 -1,4 B02B VITAMIN K AND OTHER HEMOSTATICS x x 35.730.154 x N06D ANTI-DEMENTIA DRUGS 12,9 12,5 30.096.154 10,2 L02A HORMONES AND RELATED AGENTS -2,3 1,4 29.043.416 -0,3 N04B DOPAMINERGIC AGENTS 11,0 11,6 27.632.755 9,9 L01X OTHER ANTINEOPLASTIC AGENTS 11,6 23,7 26.993.829 15,7
INHALANTS M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, -0,7 5,4 48.607.976 2,8 NON-STEROIDS C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 16,7 29,3 48.458.787 23,2 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY 4,8 10,5 47.845.796 8,1 VASCULAR EFFECTS L02B HORMONE ANTAGONISTS AND RELATED AGENTS 18,1 16,3 40.001.905 12,5 C01D VASODILATORS USED IN CARDIAC DISEASES -5,3 -0,3 37.257.508 -1,4 B02B VITAMIN K AND OTHER HEMOSTATICS x x 35.730.154 x N06D ANTI-DEMENTIA DRUGS 12,9 12,5 30.096.154 10,2 L02A HORMONES AND RELATED AGENTS -2,3 1,4 29.043.416 -0,3 N04B DOPAMINERGIC AGENTS 11,0 11,6 27.632.755 9,9 L01X OTHER ANTINEOPLASTIC AGENTS 11,6 23,7 26.993.829 15,7

C voor congestive heart failure, H voor hypertension, A voor Age ≥ 75 jaar, D voor diabetes mellitus en S 2 voor prior stroke or TIA. In de nieuwe manier van scoren wordt het ‘gewicht’ van een leeftijd boven 75 jaar als risicofactor zwaarder beoordeeld (A 2 i.p.v. A) en werden perifeer vaatlijden of (V voor “vascular disease”), een leeftijdscategorie van 65 tot 74 jaar (A voor “age”) en geslacht (Sc voor ”sex category”) als bijkomende risicofactoren toegevoegd.
-VASc, un âge de 75 ans ou plus est considéré comme un facteur de risque plus sévère (A 2 au lieu de A), et d’autres critères sont ajoutés: pathologie vasculaire (V pour ‘vascular disease’: antécédent d’infarctus du myocarde, artérite périphérique, plaque aortique), une catégorie d’âge de 65 à 74 ans (A pour « âge ») et le sexe (Sc pour ‘sex category’).

Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S et al. Oral anticoagulant and antiplatelet tjerapy and peripheral arterial disease.
Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial.

G.J. Hankey en J.W. Eikelboom: Homocysteine and vascular disease.
G.J. Hankey et J.W. Eikelboom: Homocysteine and vascular disease .

Gebruikte afkortingen: 2-3-DPG = 2,3-diphosphoglyceraat; ACTH = adrenocorticotrofin; AGE = advanced glycation end products; ATP = adenosine trifosfaat; CPD(A) = citraat fosfaat dextrose (adenine); EC = erytrocytenconcentraat; ECC = extracorporele circulatie; GvHD = graft versus host disease; H 2 O 2 = waterstofperoxyd; ICAM = inter-cellular adhesion molecule; ICU = intensive care unit; IgG = immunoglobuline G; IL = interleukine; LDH = laktaat dehydrogenase; MODS = multiple organ dysfunction syndrome, multi-orgaanfalen; NO = oxyde nitrique; NTBI = nontransferrin-bound iron; PICU = pediatric intesnsive care unit; PgE 2 = prostaglandine E 2 ; pO 2 = partielle zuurstofdruk; PS = fosfatidylserine; RAGE = advanced glycation end products receptor; RCT = randomised controled trial, gerandomiseerde gecontroleerde studie; ROS = reactive oxygen species; SIRS = systemic inflammatory response syndrome, systemisch inflammatoir responssyndroom; SNO = nitrosothiol; TNF = tumor necrosis factor; TRALI = transfusion related acute lung injury; VCAM = vascular cell adhesion molecule; VO 2 = zuurstofverbruik.
Abréviations utilisées: 2-3-DPG = 2,3-diphosphoglycérate; ACTH = adrénocorticotrophine; AGE = advanced glycation end products; ATP = adénosine triphosphate; CE = concentré érythrocytaire; CEC = circulation extra-corporelle; CPD(A) = citrate phosphate dextrose (adénine); GPIIb/IIIa = glycoprotéine IIb/IIIa; GvHD = graft versus host disease; H 2 O 2 = peroxyde d’hydrogène; ICAM = inter-cellular adhesion molecule; ICU = intensive care unit; IgG = immunoglobuline G; IL = interleukine; LDH = lactate déshydrogénase; MODS = multiple organ dysfunction syndrome, syndrome de défaillance polyviscérale; NO = oxyde nitrique; NTBI = nontransferrin-bound iron; PICU = pediatric intensive care unit; PgE 2 = prostaglandine E 2 ; pO 2 = pression partielle d’oxygène; PS = phosphatidylsérine; RAGE = récepteur d’advanced glycation end products; RCT = randomised controled trial, étude randomisée contrôlée; ROS = reactive oxygen species; SIRS = systemic inflammatory response syndrome, syndrome de réponse inflammatoire systémique; SNO = nitrosothiol; TNF = tumour necrosis factor, facteur de nécrose tumorale; TRALI = transfusion related acute lung injury; VCAM = vascular cell adhesion molecule; VO 2 = consommation d’oxygène.

BMJ 2011; 342:d2040. Lewis JR, Calver J, Zhu K, et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5 year follow-up.
Heart 2012; 98:920-5. van der Sijs IH, Ho-Dac-Pannekeet MM. The treatment of hypomagnesemia.